Navigation Links
Group Therapy: New approach to psychosis treatment could target multiple nervous system receptors
Date:2/1/2013

Philadelphia, Pa. Antipsychotic drugs, used in the treatment of psychotic disorders involving severe delusions and hallucinations, have been studied for more than 70 years. Currently available antipsychotic drugs, however, only alleviate certain symptoms, with results that vary greatly from patient to patient and frequently cause significant side effects.

A new understanding of how the brain's G-protein receptors work may soon enable a way to better customize and target antipsychotic drugs to treat specific symptoms. Researchers from Virginia Commonwealth University (VCU) will present their findings at the 57th Annual Meeting of the Biophysical Society (BPS), held Feb. 2-6, 2013, in Philadelphia, Pa.

G-protein coupled receptors (GPCRs) are responsible for activating so-called "G-proteins," internal signaling messengers that control the activity of many other internal proteins. The starring role of GPCRs in regulating a cell's activity makes them a leading pharmaceutical target: approximately 50 percent of the antipsychotic drugs produced are aimed at these important nervous system receptors.

A specific GPCR is integral to each of three key pathways for intercellular signaling, one for each of the chemical messengers dopamine, serotonin, and glutamate. But these individual GPCRs also form complexes with each other, altering their effects on signaling in the brain. The VCU team has focused on how GPCR complexes influence signaling in a distinct way from how individual GPCRs operate.

"The realization that receptors in the brain that bind and interpret dopamine, serotonin, and glutamate neurotransmitters form complexes with one another that signal very differently than when these receptors are found in isolation, promises to change the way we approach treatment of psychosis," explains VCU Ph.D. candidate Jason Younkin, who will present the team's findings.

Instead of targeting one neurotransmitter pathway at a time, Younkin and colleagues plan to target two or more at the same time. Antipsychotic drugs that target the complexes formed by the individual GPCRs will allow use of the signaling differences and could lead to more effective therapies.

"By understanding how receptor complexes signal and learning how to control these signals, it should enable the development of specific antipsychotic drugs that lack the many side effects that exist today," says VCU professor Diomedes E. Logothetis, a co-author of the study.


'/>"/>

Contact: Ellen R. Weiss
eweiss@biophysics.org
240-290-5606
American Institute of Physics
Source:Eurekalert

Related medicine news :

1. Fish Like Grouper, Barracuda May Pose Food-Poisoning Risk
2. The US Drug Watchdog Now Urges Young Women Who Suffered a Heart Attack or Blood Clotting After Taking Yaz or Yasmin Birth Control Pills to Contact the Johnson Law Group
3. US Drug Watchdog Now Urges Family Members Of Diabetics Who Used the Diabetes Drug Actos and Then Were Diagnosed with Bladder Cancer to Call The Johnson Law Group ASAP
4. Cunningham Financial Group Encourages Women to Celebrate “Cervical Health Awareness Month” by Following Important Health Tips
5. US Drug Watchdog is Now Urging Bladder Cancer Victims to Call the Johnson Law Group if They Used Diabetes Drug Called Actos Prior to Diagnosis
6. Dr. Andy Chiou elected President and Chief Executive Officer of Peoria Surgical Group, Ltd.
7. Ob/Gyn Group Urges Docs to Help Prevent Octomom-Type Multiple Births
8. The Boston Eye Group Implants First Intraocular Pressure Transducer for Glaucoma Monitoring
9. US Drug Watchdog Now Urges Users of Yaz Yasmin Birth Control Pills That Had a Stroke Or Developed Other Serious Medical Conditions to Contact The Johnson Law Group
10. Acceleration Fitness Center Now Offering Group Training Programs for Middle and High School Athletes
11. US Drug Watchdog Now Urges Families Of Diabetics Who Used The Diabetes Drug Actos, Developed Bladder Cancer and Died To Call The Johnson Law Group-For A Legal Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... 27, 2017 , ... Elisa Guajardo Carothers is not your typical author. She went from working ... nun. Now, she writes about God, when she isn’t swimming as a performing mermaid. , ... is BS! (Before Satan),” she offers a comedic look at the dysfunctions of God’s family, ...
(Date:2/27/2017)... ... 26, 2017 , ... Miro is the ultimate smart media center that offers ... movies, TV shows and much more apps for user exploration. Its innovative acoustic design ... of 1280 x 720 provides crisp images with remarkable clarity and color. The WiFi ...
(Date:2/27/2017)... BC (PRWEB) , ... February 27, 2017 , ... ... drug rehabilitation and alcohol treatment programs in British Columbia, Canada, at https://www.sunshinecoasthealthcentre.ca/ ... to its team. The new hire, Mackenzie Alsager, showcases the Centre's commitment to ...
(Date:2/27/2017)... ... ... New Jersey ranks among the top five states in the entire nation ... advanced services is growing. , Project WE vs C is a focused two-year ... non-profit partners in their fight against cancer and in support of their shared mission ...
(Date:2/26/2017)... ... February 26, 2017 , ... This is an ... world’s first to be ISO/IEC 17025:2005 INAB accredited for Der p 1 (house ... is the globally recognised standard that sets out requirements for the technical competence ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... NORWALK, Conn. , Feb. 27, 2017 /PRNewswire/ ... a meta-analysis of 28 studies, representing 2468 patients ... disease (GERD). The study entitled, " Systematic Review ... Studies of Endoscopic Radiofrequency for Treatment of Gastroesophageal ... . Authors included Ronnie Fass , MD, ...
(Date:2/27/2017)... Israel and TAMPA, Fla. , Feb. ... emerging medical device company focused on developing cerebral ... applauds the members of the FDA,s Circulatory System ... their acknowledgement of the need for cerebral protection ... "The statements shared by this FDA panel ...
(Date:2/27/2017)... (NASDAQ: IPXL ) today announced that it plans to participate ... James and Associates, 38 th Annual Institutional Investors Conference at ... Cowen and Company 37 th Annual ... Boston, MA. Barclays Global Healthcare ... FL. Individuals may listen to the ...
Breaking Medicine Technology: